This stock could get very interesting. Check today's new hire at IMNR.
SAN DIEGO, April 27 /PRNewswire/ -- The Immune Response Corporation
(Nasdaq: IMNR) today announced that Elias Nyberg, DVM, BVSc(hons), MACVS,
MRCVS, MBA, has been named Vice President, Regulatory Affairs. Dr. Nyberg
brings expertise in global regulatory affairs to the Company and has been
responsible for the successful launch of several pharmaceutical products
during his career. Dr. Nyberg has extensive experience in regulatory affairs
and quality assurance. His expertise includes regulatory strategy,
coordinating clinical trials and knowledge of FDA and European regulations and
guidelines. While at INC Research/PRA International Inc., Dr. Nyberg
developed and assessed regulatory strategy for clients and managed the entire
quality assurance process for the company. Prior to joining INC Research/PRA
International Inc., Dr. Nyberg was Worldwide Director of Regulatory Affairs
for Astra Arcus AB. Previously Dr. Nyberg served as Head of Technical
Services and Regulatory Affairs for Pfizer Pharmaceuticals, Northern European
Division, where he consecutively launched three new products. Prior to
Pfizer, Dr. Nyberg was Head of Technical Services and Regulatory Affairs and
Director of Worldwide Global Anthelmintic Business Development at Ciba-Geigy
Animal Health, World Headquarters.
"The Immune Response Corporation has numerous innovative products focused
on immune-based therapies," said Dr. Nyberg. "I look forward to moving these
products toward the goal of achievement of commercial approval and into the
marketplace."
"We are very pleased to have Dr. Nyberg join our executive management
team. His expertise in worldwide regulatory affairs, including pre-clinical,
clinical, FDA, and the European Agency for the Evaluation of Medicinal
Products (EMEA) experience will be a key asset to the Company as we continue
to develop our products," said Dennis J. Carlo, Ph.D., President and Chief
Executive Officer of The Immune Response Corporation.
Wonder why IMNR wants this man now? Or why he would accept a position with a company whose stock has ben languishing around $2-3 for a long time?
DJ |
